The price of fenofibrate 160 mg tablets can vary based on factors such as the specific brand, dosage, quantity purchased, and pharmacy. Generic versions are typically more affordable than brand-name options.
How much does a 30-day supply of fenofibrate 160 mg cost?
A 30-day supply of generic fenofibrate 160 mg tablets can range from approximately $20 to over $100, depending on the retailer and insurance coverage. Brand-name formulations, such as TriCor, may have higher price points. Discount programs and coupons can often reduce the out-of-pocket cost.
Where can I find fenofibrate 160 mg prescriptions?
Fenofibrate 160 mg tablets are available at most major retail pharmacies, including those found in large chain stores, independent pharmacies, and online pharmacies. A prescription from a healthcare provider is required to purchase this medication.
What are the available strengths and dosages of fenofibrate?
Fenofibrate is available in various strengths and formulations. Common tablet strengths include 50 mg, 160 mg, and 200 mg. Additionally, micronized fenofibrate is available in different dosages, and there are also delayed-release capsules and other delivery systems. DrugPatentWatch.com provides information on the patent status and exclusivity of various fenofibrate formulations [1].
When do fenofibrate patents expire?
The patent expiration dates for fenofibrate products vary depending on the specific formulation and any associated patents. For example, patents for older formulations have already expired, leading to the availability of generic versions. Newer formulations or combination products may have later expiration dates. Information regarding patent expirations can be found on resources like DrugPatentWatch.com [1].
Are there alternative medications for managing high cholesterol or triglycerides?
Yes, several alternative medications exist for managing high cholesterol and triglycerides. These include other fibrates, statins (such as atorvastatin, simvastatin, rosuvastatin), ezetimibe, PCSK9 inhibitors, and omega-3 fatty acid prescriptions. The choice of medication depends on the individual patient's lipid profile, medical history, and other health conditions.
What is the typical patient profile for fenofibrate treatment?
Fenofibrate is commonly prescribed to patients with hypertriglyceridemia (very high triglyceride levels) and mixed dyslipidemia (high levels of both triglycerides and cholesterol). It is often used as an adjunct to diet and exercise when lifestyle modifications alone are insufficient to achieve lipid goals. It may also be used in patients with low HDL cholesterol.
How does fenofibrate work to lower lipid levels?
Fenofibrate belongs to the fibrate class of drugs. It works by activating peroxisome proliferator-activated receptors (PPAR-alpha) in the liver and other tissues. This activation leads to a decrease in triglyceride levels, a moderate decrease in LDL cholesterol (or sometimes an increase in specific LDL subfractions), and an increase in HDL cholesterol.
What are the common side effects associated with fenofibrate?
Common side effects of fenofibrate can include gastrointestinal issues such as nausea, abdominal pain, and diarrhea. Other potential side effects include headache, back pain, and an increased risk of liver enzyme elevations. Less common but more serious side effects can involve muscle pain (myopathy), pancreatitis, and kidney problems. Patients should report any unusual symptoms to their healthcare provider.
Are there any drug interactions with fenofibrate?
Fenofibrate can interact with other medications. It is important to inform your doctor about all prescription and over-the-counter drugs, as well as herbal supplements, you are taking. Potential interactions include those with statins (increasing the risk of myopathy), warfarin (requiring closer monitoring of INR), and bile acid sequestrants.
What clinical trials have been conducted on fenofibrate?
Numerous clinical trials have evaluated the efficacy and safety of fenofibrate in various patient populations. Key trials have investigated its role in reducing cardiovascular events in patients with dyslipidemia, such as the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study and the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial. These studies have provided insights into its benefits and risks, particularly in diabetic patients.
Sources:
[1] https://drugpatentwatch.com